These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 17059999)

  • 1. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.
    Krzyzanowska K; Mittermayer F; Krugluger W; Schnack C; Hofer M; Wolzt M; Schernthaner G
    Atherosclerosis; 2006 Nov; 189(1):236-40. PubMed ID: 16414052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases?
    Işıklar OO; Barutcuoğlu B; Kabaroğlu C; Mutaf I; Özmen D; Bayındır O; Zoghi M; Uluer H
    Clin Biochem; 2012 Nov; 45(16-17):1325-30. PubMed ID: 22750146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
    Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
    Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated levels of Nε-homocysteinyl-lysine isopeptide in patients on long-term hemodialysis.
    Kolarz M; Głowacki R; Stompór T; Wyroślak J; Undas A
    Clin Chem Lab Med; 2012 Feb; 50(8):1373-8. PubMed ID: 22868801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.
    Zhang WR; Hou FF; Ning JP; Yang XB; Wu Q; Tao LJ; Chen BM; Li HY; Chang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):621-8. PubMed ID: 17062918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.
    Koyama K; Ito A; Yamamoto J; Nishio T; Kajikuri J; Dohi Y; Ohte N; Sano A; Nakamura H; Kumagai H; Itoh T
    Am J Kidney Dis; 2010 Jun; 55(6):1069-78. PubMed ID: 20430500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage.
    Notsu Y; Nabika T; Bokura H; Suyama Y; Kobayashi S; Yamaguchi S; Masuda J
    Am J Hypertens; 2009 Mar; 22(3):257-62. PubMed ID: 19057516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients.
    Coen G; Mantella D; Sardella D; Beraldi MP; Ferrari I; Pierantozzi A; Lippi B; Di Giulio S
    J Nephrol; 2009; 22(5):616-22. PubMed ID: 19809994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading.
    Wanby P; Brattström L; Brudin L; Hultberg B; Teerlink T
    Scand J Clin Lab Invest; 2003; 63(5):347-53. PubMed ID: 14599157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs.
    Emeksiz HC; Serdaroglu A; Biberoglu G; Gulbahar O; Arhan E; Cansu A; Arga M; Hasanoglu A
    Seizure; 2013 Mar; 22(2):124-7. PubMed ID: 23266348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy.
    Suliman ME; Stenvinkel P; Jogestrand T; Maruyama Y; Qureshi AR; Bárány P; Heimbürger O; Lindholm B
    Clin Nephrol; 2006 Dec; 66(6):418-25. PubMed ID: 17176913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent effects of homocysteine and dimethylarginines on cardiovascular mortality in claudicant patients with lower extremity arterial disease.
    Jud P; Hafner F; Verheyen N; Gary T; Meinitzer A; Brodmann M; Seinost G; Hackl G
    Heart Vessels; 2018 Dec; 33(12):1453-1462. PubMed ID: 29946762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.
    Tripepi G; Mattace Raso F; Sijbrands E; Seck MS; Maas R; Boger R; Witteman J; Rapisarda F; Malatino L; Mallamaci F; Zoccali C
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1714-21. PubMed ID: 21642364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
    van Guldener C; Nanayakkara PW; Stehouwer CD
    Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
    Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
    J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.
    Alsagaff MY; Thaha M; Aminuddin M; Yogiarto RM; Yogiantoro M; Tomino Y
    J Int Med Res; 2012; 40(1):340-9. PubMed ID: 22429374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.